Figure 5. YM155 is a promising therapeutic agent for HCC cells with high survivin expression as demonstrated by the orthotopic liver tumor mouse model.

(A and C) Representative images obtained with the orthotopic mouse liver tumour xenograft model. (A) Mahlavu-luciferase cells (B) HuH7-luciferase cells. Weekly images following treatment with either saline, YM155 or sorafenib were shown. (B and D) Quantitative analysis of bioluminescence imaging signals obtained for all the mice following different treatments. (E and F) IHC analysis of survivin expression in (E) Mahlavu-induced tumor and (F) HuH7-induced tumor; the induction of tumor cell apoptosis (green TUNEL⁺ cells) was also studied by TUNEL staining in Mahlavu (E) and HuH7 (F) tumor.